Your browser doesn't support javascript.
loading
Botulinum Toxin Type A (BoNT-A) Use for Post-Stroke Spasticity: A Multicenter Study Using Natural Language Processing and Machine Learning.
Antón, María Jesús; Molina, Montserrat; Pérez, José Gabriel; Pina, Santiago; Tapiador, Noemí; De La Calle, Beatriz; Martínez, Mónica; Ortega, Paula; Ruspaggiari, María Belén; Tudela, Consuelo; Conejo, Marta; Leno, Pedro; López, Marta; Marhuenda, Carmen; Arias-Cabrales, Carlos; Maisonobe, Pascal; Herrera, Alberto; Candau, Ernesto.
Afiliación
  • Antón MJ; Department of Physical Medicine and Rehabilitation, Rio Hortega University Hospital, 47007 Valladolid, Spain.
  • Molina M; Department of Physical Medicine and Rehabilitation, University Hospital of Fuenlabrada, 28942 Madrid, Spain.
  • Pérez JG; Department of Physical Medicine and Rehabilitation, Son Espases University Hospital, 07210 Palma de Mallorca, Spain.
  • Pina S; Department of Physical Medicine and Rehabilitation, General University Hospital, 12004 Castellón, Spain.
  • Tapiador N; Department of Physical Medicine and Rehabilitation, University Hospital Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.
  • De La Calle B; Department of Physical Medicine and Rehabilitation, Rio Hortega University Hospital, 47007 Valladolid, Spain.
  • Martínez M; Department of Physical Medicine and Rehabilitation, University Hospital of Fuenlabrada, 28942 Madrid, Spain.
  • Ortega P; Department of Physical Medicine and Rehabilitation, University Hospital Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.
  • Ruspaggiari MB; Department of Physical Medicine and Rehabilitation, Son Espases University Hospital, 07210 Palma de Mallorca, Spain.
  • Tudela C; Department of Physical Medicine and Rehabilitation, General University Hospital, 12004 Castellón, Spain.
  • Conejo M; Department of Physical Medicine and Rehabilitation, University Hospital of Fuenlabrada, 28942 Madrid, Spain.
  • Leno P; Department of Physical Medicine and Rehabilitation, Son Espases University Hospital, 07210 Palma de Mallorca, Spain.
  • López M; Department of Physical Medicine and Rehabilitation, General University Hospital, 12004 Castellón, Spain.
  • Marhuenda C; Department of Physical Medicine and Rehabilitation, University Hospital Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.
  • Arias-Cabrales C; Savana Research S.L, 28004 Madrid, Spain.
  • Maisonobe P; Department of Biometry, Ipsen Pharma, 92100 Boulogne-Billancourt, France.
  • Herrera A; Medical Affairs, Ipsen Pharma, 28050 Madrid, Spain.
  • Candau E; Department of Physical Medicine and Rehabilitation, Rio Hortega University Hospital, 47007 Valladolid, Spain.
Toxins (Basel) ; 16(8)2024 Aug 02.
Article en En | MEDLINE | ID: mdl-39195750
ABSTRACT
We conducted a multicenter and retrospective study to describe the use of botulinum toxin type A (BoNT-A) to treat post-stroke spasticity (PSS). Data were extracted from free-text in electronic health records (EHRs) in five Spanish hospitals. We included adults diagnosed with PSS between January 2015 and December 2019, stratified into BoNT-A-treated and untreated groups. We used EHRead® technology, which incorporates natural language processing and machine learning, as well as SNOMED CT terminology. We analyzed demographic data, stroke characteristics, BoNT-A use patterns, and other treatments. We reviewed the EHRs of 1,233,929 patients and identified 2190 people with PSS with a median age of 69 years; in total, 52.1% were men, 70.7% had cardiovascular risk factors, and 63.2% had suffered an ischemic stroke. Among the PSS patients, 25.5% received BoNT-A at least once. The median time from stroke to spasticity onset was 205 days, and the time from stroke to the first BoNT-A injection was 364 days. The primary goal of BoNT-A treatment was pain control. Among the study cohort, rehabilitation was the most common non-pharmacological treatment (95.5%). Only 3.3% had recorded monitoring scales. In conclusion, a quarter of patients with PSS received BoNT-A mainly for pain relief, typically one year after the stroke. Early treatment, disease monitoring, and better data documentation in EHRs are crucial to improve PSS patients' care.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Procesamiento de Lenguaje Natural / Toxinas Botulínicas Tipo A / Accidente Cerebrovascular / Aprendizaje Automático / Espasticidad Muscular Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Toxins (Basel) Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Procesamiento de Lenguaje Natural / Toxinas Botulínicas Tipo A / Accidente Cerebrovascular / Aprendizaje Automático / Espasticidad Muscular Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Toxins (Basel) Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza